[1] Timmins MA, Wagner SD, Ahearne MJ. The new biology of PTCL-NOS and AITL: current status and future clinical impact[J]. Br J Haematol, 2020, 189(1):54-66. DOI:10.1111/bjh.16428.
[2] Chiba S, Sakata-Yanagimoto M. Advances in understanding of angioimmunoblastic T-cell lymphoma[J]. Leukemia, 2020, 34(10):2592-2606. DOI:10.1038/s41375-020-0990-y.
[3] Wawrzycki B, Prystupa A, Szumiło J, et al. Fever, rash, and eosinophilia-early signs of angioimmunoblastic T-cell lymphoma[J]. Ann Agric Environ Med, 2021, 28(3):525-530. DOI: 10.26444/aaem/140594.
[4] Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma[J]. Blood, 2017, 129(9):1095-1102. DOI:10.1182/blood-2016-09-692541.
[5] Pritchett JC, Yang ZZ, Kim HJ, et al. High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma[J]. Leukemia, 2022, 36(1):165-176. DOI:10.1038/s41375-021-01321-2.
[6] Xie Y, Jaffe ES. How i diagnose angioimmunoblastic T-cell lymphoma [J]. Am J Clin Pathol, 2021, 156(1):1-14. DOI:10.1093/ajcp/aqab090.
[7] Moskowitz AJ. Practical treatment approach for angioimmunoblastic T-Cell lmphoma[J]. J Oncol Pract, 2019, 15(3):137-143. DOI:10.1200/JOP.18.00511.
[8] Leval DL. Approach to nodal-based T-cell lymphomas[J]. Pathology, 2020, 52(1):78-99. DOI:10.1016/j.pathol.2019.09.012.
[9] Yabe M, Dogan A, Horwitz SM, et al. Angioimmunoblastic T-cell lymphoma[J]. Cancer Treat Res,2019,176:99-126. DOI:10.1007/978-3-319-99716-2_5.
[10] Sharifi-Noghabi H, Peng S, Zolotareva O, et al. AITL: adversarial inductive transfer learning with input and output space adaptation for pharmacogenomics[J]. Bioinformatics, 2020,36(1): i380-i388. DOI:10.1093/bioinformatics/btaa442.
[11] Tari G, Lemonnier F, Morschhauser F. Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment [J]. Curr Opin Oncol, 2021, 33(5):400-405. DOI:10.1097/CCO.0000000000000773.
[12] Advani RH, Skrypets T, Civallero M, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell project[J]. Blood, 2021, 138(3):213-220. DOI:10.1182/blood.2020010387.
[13] Lemonnier F, Cairns RA, Inoue S, et al. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development [J]. Proc Natl Acad Sci, 2016, 113(52):15084-15089. DOI: 10.1073/pnas.1617929114.
[14] Leca J, Lemonnier F, Meydan C, et al. IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment [J]. Cancer Cell, 2023, 41(2):323-339. DOI:10.1016/j.ccell.2023.01.003.
[15] Ohshima K, Miyoshi H, Yamada K. The microenvironment and immune status of peripheral T-cell lymphoma: focusing on AITL and ATLL [J]. Rinsho Ketsueki, 2018, 59(5): 574-587. DOI:10.11406/rinketsu.59.574.
[16] Zhou Y, Rosenblum MK, Dogan A, et al. Cerebellar EBV-associated diffuse large B cell lymphoma following angioimmunoblastic T cell lymphoma[J]. J Hematop, 2015, (4):235-241. DOI: 10.1007/s12308-015-0241-8.
[17] Witalis M, Chang J, Zhong MC, et al. Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk [J]. Blood Adv, 2020, 4(5):868-879. DOI:10.1182/bloodadvances.2019001114.
[18] Lammoglia Cobo MF, Ritter J, Gary R, et al. Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL[J]. PLoS Pathog, 2022, 22, 18(4): e1010206. DOI:10.1371/journal.ppat.1010206.
[19] Kameda K, Kako S, Kim SW, et al. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL[J]. Leukemia, 2022, 36(5): 1361-1370. DOI:10.1038/s41375-022-01545-w.
[20] Mohammed Saleh MF, Kotb A, Abdallah GEM, et al. Recent advances in diagnosis and therapy of angioimmunoblastic T cell lymphoma[J]. Curr Oncol, 2021, 28(6):5480-5498. DOI:10.3390/curroncol28060456.
|
